Zentalis Pharmaceuticals (ZNTL) Free Cash Flow (2019 - 2026)
Zentalis Pharmaceuticals' quarterly Free Cash Flow came in at -$33.0 million in Q1 2026, down 1.08% year-on-year from -$33.4 million in Q1 2025, and down 6.63% quarter-over-quarter from -$30.9 million in Q4 2025.
Zentalis Pharmaceuticals has reported Free Cash Flow for 8 years, with the latest figure at -$33.0 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 1.08% year-over-year to -$33.0 million; the trailing twelve-month figure through Mar 2026 stood at -$125.6 million (up 17.21% YoY), and the FY2025 full-year result was -$125.2 million, up 26.79% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$33.0 million, down from -$30.9 million in the prior quarter.
- The five-year high for Free Cash Flow was -$27.0 million in Q3 2025, with the low at -$79.6 million in Q2 2023.
- Average Free Cash Flow over 5 years is -$41.4 million, with a median of -$38.8 million recorded in 2023.
- Year-over-year, Free Cash Flow tumbled 85.57% in 2023 and surged 55.62% in 2024.
- Tracing ZNTL's Free Cash Flow over 5 years: stood at -$37.5 million in 2022, then declined by 8.76% to -$40.8 million in 2023, then gained by 2.62% to -$39.7 million in 2024, then advanced by 22.07% to -$30.9 million in 2025, then slipped by 6.63% to -$33.0 million in 2026.
- The last three Free Cash Flow figures came in at -$33.0 million (Q1 2026), -$30.9 million (Q4 2025), and -$27.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | -32.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.99 Mn |
| Mar 31, 2026 | -32.99 Mn |
| Dec 31, 2025 | -30.94 Mn |
| Dec 31, 2025 | -30.94 Mn |
| Sep 30, 2025 | -26.96 Mn |
| Sep 30, 2025 | -26.96 Mn |
| Jun 30, 2025 | -34.71 Mn |
| Jun 30, 2025 | -34.71 Mn |
| Mar 31, 2025 | -32.64 Mn |
| Mar 31, 2025 | -32.64 Mn |
| Dec 31, 2024 | -39.70 Mn |
| Dec 31, 2024 | -39.70 Mn |
| Sep 30, 2024 | -44.05 Mn |
| Sep 30, 2024 | -44.05 Mn |
| Jun 30, 2024 | -35.32 Mn |
| Jun 30, 2024 | -35.32 Mn |
| Mar 31, 2024 | -52.01 Mn |
| Mar 31, 2024 | -52.01 Mn |
| Dec 31, 2023 | -40.77 Mn |
| Dec 31, 2023 | -40.77 Mn |
| Sep 30, 2023 | -38.76 Mn |
| Sep 30, 2023 | -38.76 Mn |
| Jun 30, 2023 | -79.59 Mn |
| Jun 30, 2023 | -79.59 Mn |
| Mar 31, 2023 | -49.28 Mn |
| Mar 31, 2023 | -49.28 Mn |
| Dec 31, 2022 | -37.49 Mn |
| Dec 31, 2022 | -37.49 Mn |
| Sep 30, 2022 | -35.50 Mn |
| Sep 30, 2022 | -35.50 Mn |
| Jun 30, 2022 | -42.89 Mn |
| Jun 30, 2022 | -42.89 Mn |
| Mar 31, 2022 | -50.42 Mn |
| Mar 31, 2022 | -50.42 Mn |
| Dec 31, 2021 | -39.21 Mn |
| Dec 31, 2021 | -39.21 Mn |
| Sep 30, 2021 | -37.41 Mn |
| Sep 30, 2021 | -37.41 Mn |
| Jun 30, 2021 | -46.05 Mn |
| Jun 30, 2021 | -46.05 Mn |
| Mar 31, 2021 | -37.54 Mn |
| Mar 31, 2021 | -37.54 Mn |
| Dec 31, 2020 | -28.02 Mn |
| Dec 31, 2020 | -28.02 Mn |
| Sep 30, 2020 | -20.61 Mn |
| Sep 30, 2020 | -20.61 Mn |
| Jun 30, 2020 | -22.06 Mn |
| Jun 30, 2020 | -22.06 Mn |
| Mar 31, 2020 | -16.90 Mn |
| Mar 31, 2020 | -16.90 Mn |
| Dec 31, 2019 | -12.88 Mn |
| Dec 31, 2019 | -12.88 Mn |
| Sep 30, 2019 | -10.10 Mn |
| Sep 30, 2019 | -10.10 Mn |
| Jun 30, 2019 | -7.16 Mn |
| Jun 30, 2019 | -7.16 Mn |
| Mar 31, 2019 | -9.01 Mn |
| Mar 31, 2019 | -9.01 Mn |